Episodes

  • #4 - Fundraising Through the Ecosystem - The Irish Model: Joseph Snyder & Cristiano Fontana
    Jun 15 2025

    Hosts:

    Joseph Snyder

    Head of Talent and Co-Founder, Lifeblood

    https://www.linkedin.com/in/josephasnyder1/

    Cristiano Fontana

    Head of Advisory, Lifeblood

    https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

    Guests:

    Tim Jones

    CEO, Symphysis Medical

    Tim Jones is the CEO of SymPhysis Medical, an Irish MedTech start-up developing innovative solutions for the management of pleural effusions. Prior to founding SymPhysis Medical, Tim held key roles at Medtronic, where he gained hands-on experience in global MedTech operations, product development, and market access strategies within one of the world’s leading medical technology companies. At SymPhysis, Tim has led the company from early-stage concept through clinical validation, securing private investment and highly competitive non-dilutive funding, while earning international recognition for advancing patient-centric design in MedTech innovation.

    https://www.linkedin.com/in/tim-jones-1a004040/

    Daniel O-Mahony

    Partner, Seroba

    Daniel O’Mahony is a Partner at Seroba, where he leverages over two decades of experience in life sciences, spanning product development, strategic planning, licensing, corporate venturing, and intellectual property commercialisation. He began his investment career in corporate venture at Elan Corporation and later became a partner at Kernel Capital, before joining Seroba in 2009.

    With a strong foundation in both academia and technology transfer, Daniel previously held research and teaching roles at Trinity College Dublin, the Geisinger Clinic in Pennsylvania, and University College Dublin. He also led the Technology Transfer Office at the University of Galway, where he secured several high-value licensing agreements.

    https://www.linkedin.com/in/daniel-o-mahony-b02a1413/

    Joey Mason

    Venture Partner, Claret Capital Partners

    Joey Mason has spent 30 years working in life sciences as an investor, entrepreneur, financier, director, mentor and advisor. He is currently a Venture Partner at Claret Capital Partners, a London-based venture debt firms. Joey also serves as a Venture Advisor to Sofinnova Partners, one of Europe’s leading healthcare investment firm.

    Joey has significant experience in most segments of the industry – medtech, pharma/ biotech, diagnostics, health IT and techbio. He has served on the boards of 20 private and public companies in Ireland, Europe and the USA and also on the board of EVCA (InvestEurope), the trade association for the private equity industry in Europe. In 2021, he co-founded Duplex Capital Partners to advise companies innovating in the digitalisation of life sciences. Prior to this he led a Life Science fund at M Ventures, Merck KGaA’s corporate venture arm, from 2018 – 2020 in Amsterdam, having spent 10 years at Delta Partners from 2004, where he was responsible for its most profitably exited investment.

    https://www.linkedin.com/in/joey-mason/

    Show more Show less
    1 hr and 9 mins
  • #3 - Networking & Building Connections in MedTech: Joseph Snyder & Cristiano Fontana
    Jun 4 2025

    Hosts:

    Joseph Snyder

    Head of Talent and Co-Founder, Lifeblood

    https://www.linkedin.com/in/josephasnyder1/

    Cristiano Fontana

    Head of Advisory, Lifeblood

    https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

    Guests:

    Paul Grand

    Founder & CEO, MedTech Innovator

    Paul is the founder and CEO of MedTech Innovator. He created and managed MedTech Innovator as a program within RCT Ventures from 2013 – 2016. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. He spent 11 years as Director and Managing Director at RCT Ventures, the investment arm of Research Corporation Technologies, Inc. Prior to RCT, Paul was co-founder and CEO of startups in the MedTech, pharma, and tech sectors.

    https://www.linkedin.com/in/paulgrand/

    Stephen Levin, Editor-in-Chief, Medtech Strategist/Market Pathways

    Managing Partner, Innovation In Medtech, LLC

    Stephen Levin has spent more than 25 years covering the life sciences industry, writing and speaking primarily on medical technology worldwide. In 2014, Levin and his long-time colleague, David Cassak, launched Innovation In Medtech, LLC, which features a pair of global medtech publications, MEDTECH STRATEGIST (focusing on business development) and MARKET PATHWAYS (covering medtech regulatory, reimbursement and policy issues), along with industry-leading investor conferences in Dublin, Ireland, and California.

    Levin formerly was Editor-in-Chief/Medical Devices at Elsevier Business Intelligence (EBI), from 2008 until EBI was acquired by Informa in 2013. At EBI, he directed the editorial coverage for the company’s medtech publications, including IN VIVO, START-UP, MEDTECH INSIGHT, THE GRAY SHEET, and THE SILVER SHEET, along with the content for the Investment In Innovation (IN3) series of medical device partnering conferences. EBI was formed in 2008 when Elsevier acquired Windhover Information and combined Windhover with FDC Reports. He had joined Windhover in 1997, where as Executive Editor, he supervised the editorial operations of IN VIVO, START-UP, and MEDTECH INSIGHT, while also covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel.

    https://www.linkedin.com/in/stephen-levin-3415a591/

    Ken Nelson

    Partner, MedTech Advantage Fund

    Ken Nelson is a seasoned leader and innovator in digital health and MedTech, with over 20 years of experience spanning Fortune 500 companies, high-growth startups, and successful exits. He has played a pivotal role in shaping the commercial success of groundbreaking technologies in digital health, wearables, and cardiac remote patient monitoring.

    Ken’s leadership helped build three of the top four market share companies in the cardiac monitoring space, including BioTelemetry (#1, acquired by Philips for $2.8B), iRhythm (#2, IPO), and Bardy Diagnostics (#4, acquired by HillRom for over $400). At Bardy Diagnostics, he led global commercialization of the CAM Patch, securing over $35M in venture funding and driving the company’s rapid growth.

    Ken brings deep expertise in commercialization, startup scaling, strategic partnerships, and M&A. His specialties include sales and marketing leadership, disruptive product launches, venture fundraising, and strategic operations across cardiology, electrophysiology, and diagnostics.

    https://www.linkedin.com/in/ken-nelson-56aaa34/

    Show more Show less
    1 hr and 6 mins
  • #2 - Investment & Economic Outlook: Joseph Snyder & Cristiano Fontana
    Apr 26 2025

    Hosts:

    Joseph Snyder

    Head of Talent and Co-Founder, Lifeblood

    https://www.linkedin.com/in/josephasnyder1/

    Cristiano Fontana

    Head of Advisory, Lifeblood

    https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

    Guests:

    David Uffer

    Managing Director, Trinity Life Sciences

    David brings over 30 years of executive level experience dedicated to MedTech to Trinity. He has experience across strategy consulting, transaction advisory, venture investing, as well as HEOR, market access and clinical affairs advisory all focused on device, diagnostics and digital health.

    Before joining Trinity David led MedTech portfolio and investing at General Inception, a venture capital firm. Prior to that, Dave spent five years leading the MedTech practice as Senior Partner at Alira Health, a global advisory firm with practices across all healthcare consulting and execution.

    In previous roles David led Business Development for a $5B division of Medtronic (legacy Covidien) in their respiratory, monitoring and med/surg products covering 22 business lines. He ran deals in M&A, distribution, co-development and also executed minority equity investments. Prior to Medtronic, David was Director of Corporate Development at Hologic running strategy and executing deals across gyn surgery, breast health, and molecular diagnostics.

    https://www.linkedin.com/in/david-uffer-00a176/

    Jonathan Norris

    Managing Director, VC Relationship Managment, HSBC Innovation Banking

    Jonathan Norris is a Managing Director at HSBC Innovation, with over two decades of experience in the healthcare and life sciences sector. A former litigation attorney, Jonathan has been immersed in healthcare investing since 1999, with a particular focus on equity and debt strategy across BioPharma, Medical Devices, Diagnostics/Tools, and Digital Health.

    At HSBC Innovation, Jonathan advises both investors and executives by analyzing historical and current market trends, including venture investments, IPO activity, and M&A. He regularly supports C-level leadership with business planning, exit strategy, and access to capital, and is known for his insightful thought leadership on healthcare venture funding and deal flow.

    Jonathan has authored numerous analyses on the flow of capital into the healthcare ecosystem and continues to be a trusted voice in the industry, helping shape strategic decision-making for both startups and investors.

    https://www.linkedin.com/in/jonathan-norris-248556/

    Diana Saraceni

    Founder and Managing Partner, Panakes Partners

    Diana Saraceni is a seasoned venture capitalist with over 20 years of experience in pan-European investments across Digital, Cleantech/Deep Tech, and Healthcare/Life Sciences. She is the Co-Founder and Managing Partner at Panakès Partners, where she plays a leading role in funding and scaling innovative startups.

    Diana has successfully raised and managed multiple funds and has guided numerous portfolio companies to exits through trade sales and IPOs. Beyond investing, she actively contributes to the innovation ecosystem by serving on selection committees, chairing startup competitions, and advocating for greater gender balance in technology. She also lectures on Entrepreneurship and Venture Capital at leading academic institutions across Europe.

    https://www.linkedin.com/in/diana-saraceni-74994/

    Show more Show less
    58 mins
  • #1 - Why You Aren't Raising Capital: Joseph Snyder & Cristiano Fontana
    Apr 26 2025

    Hosts:

    Joseph Snyder

    Head of Talent and Co-Founder, Lifeblood

    https://www.linkedin.com/in/josephasnyder1/

    Cristiano Fontana

    Head of Advisory, Lifeblood

    https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

    Guests:

    Thomas Busby

    Director, Outcome Capital

    Thomas F. Busby is a Director at Outcome Capital, having joined the Firm in 2015. Drawing from transactional experience spanning the breadth of life science verticals, Mr. Busby’s primary coverage and focus spans the medical device, digital health, and life sciences services segments.

    Mr. Busby has advised dozens of senior management teams and Boards on a variety of complex strategic issues, ranging from transaction process considerations to valuation and transaction structure, value proposition communication and buyer analysis, along with the plethora of managerial challenges faced in executing complex corporate events. Devoted to the industry he serves, Mr. Busby has been published in leading industry publications, including: MedTech Strategist, Life Science Leader, and The Pharma Letter. Mr. Busby has also served as a panelist, moderator and judge for numerous industry events and is a Board Member of HealthTech Build, a Boston-based digital health innovation group. He also served as an External Advisory Board Member for the UMASS Chan Medical School Bridge Fund.

    Umaima Ahmad

    CEO, 52North

    Umaima is CEO and co-founder of 52North, a multi-award winning med-tech company focused on improving urgent care. The company has raised over $11m in funding and its first product was awarded breakthrough status by the UK Government in 2024. Previously a business development professional, and a banking lawyer, Umaima has held a number of non-executive roles within health-tech. She is a seasoned negotiator of significant M&A and licensing transactions with values in the billions of dollars, involving pharmaceutical assets across multiple therapy areas which have had significant tangible impact on patient treatment pathways and health outcomes. Umaima is a graduate of King’s College London, the University of Strasbourg and BPP Law School and holds an MPhil in Bioscience Enterprise from the University of Cambridge.

    https://www.linkedin.com/in/umaima-ahmad/

    Tracy McNeal

    CEO and President, Materna Medical

    Tracy MacNeal is the CEO of Materna Medical. She is a chemical engineer, a Duke MBA, a healthcare entrepreneur, and a medical technology investor. A driver for health equity, Tracy also serves on the Board of Directors for AdvaMed, the national industry organization for medical devices, and leads their Women’s Health Equity Initiative. Tracy is President and CEO of Materna Medical, a novel, post-revenue OBGYN company with one product on the market and an exciting clinical stage product seeking to reduce maternal injury, shorten delivery time, reduce C-sections, and improve postpartum recovery for new moms.

    https://www.linkedin.com/in/tracymacneal/

    Martin Gomez

    Partner, Goodwin Procter LLP

    Martin Gomez is a partner in Goodwin’s Technology and Life Sciences Business Unit, specializing in intellectual property matters, and is a co-leader of the Firm’s MedTech and Artificial Intelligence practice groups. Martin focuses his practice on advising technology and life sciences companies of all sizes (including startups), and their investors, in corporate and especially intellectual property matters throughout the business life cycle, including new company formation, IP protection, fundraising, strat

    Show more Show less
    1 hr